Summary: Biofidelity’s new Aspyre Clinical Test for Lung delivers comprehensive genomic profiling for non-small cell lung cancer (NSCLC) patients from tissue or liquid biopsy samples within two days, enabling faster and more effective treatment decisions.
Takeaways:
- Rapid Turnaround Time: Aspyre Clinical Test for Lung provides next-day genomic profiling results for NSCLC patients, addressing delays in traditional molecular testing that often take weeks.
- Comprehensive Genomic Analysis: The test analyzes DNA and RNA from both blood and tissue samples, detecting somatic mutations and gene fusions without the need for separate assays, enhancing diagnostic efficiency.
- Improved Patient Outcomes: By enabling timely biomarker-based treatment decisions, the test supports better therapeutic outcomes and broader access to genomic testing for advanced lung cancer patients.
Biofidelity, a genomic solutions provider, announced the launch of Aspyre Clinical Test for Lung for liquid biopsy samples. Aspyre Clinical Test for Lung analyzes all guideline-recommended genes for non-small cell lung cancer (NSCLC) patients in both DNA and RNA from tissue and blood within two days, benefitting patients by enabling earlier treatment decisions.
“Currently, patients who are fortunate enough to receive molecular testing often have to wait weeks for the results, with many tests failing altogether,” says Biofidelity Co-Founder and CEO Barnaby Balmforth, PhD. “Aspyre Clinical Test for Lung’s unmatched next day turnaround time coupled with its best-in-class performance from tissue and blood and proven performance with challenging samples makes Simplified Genomic Profiling (SGP) via Aspyre a game-changer for patients and the clinicians treating them.”
Detecting Somatic Mutations
Utilizing either tissue or blood samples, Aspyre Clinical Test for Lung detects somatic mutations from DNA and gene fusions directly from RNA, maximizing the ability to identify mutations and fusions, while avoiding the extra time, additional sample requirements and added expense of running separate assays.
Data supporting the launch will be presented at the International Society of Liquid Biopsy Annual Congress, Nov. 23-25, 2024 in Denver, Colorado during the scientific poster session.
“As a practicing oncologist, it is incredibly frustrating to see time and time again, patients with advanced and metastatic lung cancer being initiated on suboptimal therapy due to the lack of timely biomarker test results. This has most likely led to poorer outcomes and potentially reduced patient tumor response and survival,” says Steven Wong, MD, a prominent medical oncologist who practices in several oncology practices across Southern California. “We always want to provide our patients the best treatment possible. Having the option to analyze both blood and tissue samples, DNA and RNA via a simple, fast and reliable test will undoubtedly enable broader access to genomic testing and ultimately better outcomes for patients. Using the most optimal therapy is the most cost effective way to manage patients with cancer.”
Featured image: Aspyre Clinical Testing Boxes. Photo: Biofidelity
